| Name | TC-MCH 7c |
| Description | TC-MCH 7c is an oral, selectable and blood-brain barrier penetrating MCH1R antagonist with IC50 performance of 5.6 nM against hMCH1R, and TC-MCH 7c is a phenylpyridone derivative with MCH1R Ki of 3.4 nM against human. In mice, MCH1R Ki was 3.0 nM. |
| In vitro | In [Ca2+]i mobilization, TC-MCH 7c has an IC50 of 9.7 μM for MCH1R [1]. TC-MCH 7c has IC50s of 23 nM and 9.0 μM for FLIPR and hERG, respectively[2]. |
| In vivo | In DIO mice model, TC-MCH 7c (oral; 3-30 mg/kg; once-daily for 1.5 months) shows excellent body weight reduction in a dose-dependent manner [1]. TC-MCH 7c(oral; 3 to 30mg /kg) and 30mg /kg at 2, 15 and 24 h were 5.1, 1.8 and 0.7 μM, respectively[2]. |
| Storage | 02 | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 55 mg/mL (134.65 mM), Sonication is recommended.
|
| Keywords | TC-MCH 7c | TCMCH 7c | TC MCH 7c | mouse MCH1R | MelaninconcentratingHormoneReceptor(MCHR) | MelaninconcentratingHormoneReceptor | Melaninconcentrating Hormone Receptor (MCHR) | Melanin-concentrating Hormone Receptor | MCHR | MCH1-R | hMCH1R |
| Inhibitors Related | Monomethyl fumarate | Pamoic acid disodium | Azathioprine | CRTh2 antagonist 2 | Fezagepras sodium | Benzyl nicotinate | 1-methoxycyclopropanecarboxylic acid | TUG-1375 | CAY10595 | TUG-424 | Timapiprant | Tricosanoic acid |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | CNS-Penetrant Compound Library | Inhibitor Library | Orally Active Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | GPCR Compound Library | Anti-Cancer Compound Library |
United States
